IBD-Associated Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 20 December 2025 | Viewed by 71
Special Issue Editor
Special Issue Information
Dear Colleagues,
Patients with long-term inflammatory bowel disease (IBD) are at increased risk of developing cancer, underscoring the critical importance of early diagnosis and treatment. However, at present, there are no established methods for the early detection of IBD-associated cancers, nor are there standardized treatments based on disease stage and pathology or clear guidelines for post-treatment follow-up. In the case of ulcerative colitis, the gold standard for surveillance is a combination of colonoscopy and pathological biopsy examination. Nevertheless, it is not uncommon for cancers to be detected at an advanced stage, even with surveillance. Moreover, the optimal treatment strategy—whether endoscopic treatment, local resection, or total colectomy—based on the detected lesion remains unclear. On the other hand, in Crohn’s disease, racial differences in the prevalence of affected areas have been observed, and an effective surveillance program has yet to be firmly established. Surgery is the primary treatment modality, and minimally invasive surgeries have become more widespread in recent years. However, the prognosis remains poor, and improving treatment outcomes remains a significant challenge.
To advance the understanding of IBD-associated cancers, we aim to extract key insights into the mechanisms of carcinogenesis, surveillance methods, treatment strategies, and follow-up protocols from both basic and clinical research perspectives.
Dr. Takayuki Ogino
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- IBD-associated cancer
- Crohn’s disease
- ulcerative colitis
- colorectal cancer
- small bowel cancer
- chemotherapy
- radiotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
